Carna Biosciences
4572.TTSE GROWTHPharmaceutical
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥491m | ¥542m | ¥1.5bn | ¥1.2bn | ¥1.9bn | ¥1.0bn |
| Operating income | −¥2.0bn | −¥2.1bn | −¥1.2bn | −¥1.3bn | −¥558m | — |
| Ordinary income | −¥2.1bn | −¥2.1bn | −¥1.2bn | −¥1.4bn | −¥549m | −¥1.1bn |
| Total assets | ¥1.1bn | ¥2.5bn | ¥4.1bn | ¥4.0bn | ¥5.3bn | ¥4.7bn |
| Net assets / equity | ¥66m | ¥2.2bn | ¥3.6bn | ¥3.4bn | ¥4.2bn | ¥3.7bn |
| EPS (basic) | ¥-112.09 | ¥-121.08 | ¥-70.53 | ¥-103.2 | ¥-43.83 | ¥-91.84 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 71 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 188 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 71 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 188 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 71 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 47 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 192 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 49 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 73 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 47 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 192 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 49 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 73 figures · EDINET |
22 more reports are still being processed.
Segments · FY ended 2025-12
| Segment | External sales | Profit |
|---|---|---|
| Drug Discovery Business | — | −¥2.0bn |
| Drug Discovery Support Business | ¥579m | −¥51m |
| Adjustments & eliminations | — | — |
| Total | ¥579m | −¥2.1bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.